Get started

Biotech

$MIRM november update*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on 10/29/21 at $15.70 per share. Our first take profit is at $26. Mirum Pharmaceuticals $MIRM released their 3rd quarter earnings today after market close. In this report they announced a loss of -$1.55 per share on revenue of $5.0 million. This earnings beat is staggering, especially when acknowledging the fact that the revenue consensus was only $0.8 million. $MIRM is still an under the radar company currently, but a revenue beat of 502.4% will definitely turn some heads. In addition, post-earnings five insiders accumulated a vast amount of shares. These insiders know what's coming, and lucky for us we do too. Our first take profit is honestly a huge underestimate of this companies potential, and in the future we may have to make some major adjustments. This is a buy and throw away the key type of investment. My teams holding! Will you? OUR ENTRY: $15.70 FIRST TAKE PROFIT: $26 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:MIRMLong
by SimplyShowMeTheMoney
4
Possibly the most undervalued stock on the TSX!- $19M mkt cap / 11M float - $28.4M cash eq. - $17.1M Q3 revenue / $7M adjusted EBITDA - Options at $3.27 - Warrants at $3.53 - Enterprise value (as of Sep 30, 2021): $103.8M!! - Canadian Commercial business is focused on Pain, Neurology, Allergy, And Dermatology therapeutics. - 17 Global Distribution Partners across 31 Countries. - Over 100 global patents and patent applications - 20+ products, 7 proprietary products, ~ 100 employees
MLong
by wealth_bakery
TARGET HIT $PFR 9.05% in 14 days TARGET HIT $PFR 9.05% in 14 days Wooo hoooo…. Great game!!! Definitely room for this to go higher... —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your own due diligence. If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can. Have fun, y’all!! (\_/) ( •_•) / >🚀
NYSE:PFE
by SPYder_QQQueen_Trading
BNGO ready for a breakout?Bionano Genomics, it is in the field of gene sequencing. The company`s product, Saphyr, uses optical genome mapping to help detect structural variations in gene sequencing. Bionano recently acquired BioDiscovery for $100 million, which is a leader in clinical software production. The acquisition may facilitate adoption of the Saphyr system, in $4 billion market segment. I see a strong support at this level and an upside, according to BTIG Research of $10 per share.
NASDAQ:BNGOLong
by TopgOptions
3
Possible Wykoff accum. after price discovery - NUMI shroomboomNUMI could be in the midst of a Wykoff accumulation. ^ means a pro, v means a con. I am trying to look at both sides to reduce emotionally-blinded decision making. Looking from far, there is systematic market risk: v institutions adopting Bitcoin, resulting in broad market exposure to USDT fraud risk and Bitcoin volatility v GME apes stressing underlying system A broader market pullback or turn to bear market can affect any stock's price. Looking at the sector: ^ I believe I know that psychedelics work, and are safe ^ mental health a huge industry that impacts all sectors because..humans, and looks to grow due to COVID v proper testing can take time and money v Canadian election can affect the path the sector takes. I believe the psychedelics market is in the nascent stages of a multi-year bull market. Valuing companies in the sector right now is difficult. Looking at the company: ^ one of the few companies in the sector that actually has revenue ^ lower risk of `going to zero` because not focused on novel compounds ^ is focused on creating IP v lower potential to moon because not focused on patenting compounds v rank-ordered within industry, less focused on making money, more focused on helping people and making help accessible ^ outstanding team and network ^ focused on psychedelic-assisted psychotherapy (similar to shamanic-assisted tripping, which is an ancient, proven methodology) ^ $63.2 million cash position (1/3 current market value @~$0.87 ^ YOY revenue is expected to increase by ~100% v not much attention on reddit (hey, it seems to matter) ^ lower volatility due to lack of meme-retail involvement v has diluted shares in the past The company is solid, growing through acquisitions and research, and a leader in the sector. Numinus is licence by Health Canada to cultivate, extract and sell psychedelic compounds. They also have a dealer's licence to import, export, possess, test and distribute MDMA, psilocybin, psilocin, DMT and mescaline. v my understanding is that ibogaine is the most effective psychedelic specifically for opioid addiction. but entails cardiac risk, but numinus does not seem to be working with ibogaine-derived compounds The book: Bear Market Trading Strategies by Matthew R Kratter say that if a stock moves above it's 200 day MA, one can consider shorting. Playing with this logic, NUMI is below it's 200 day MA in what looks to be a possible multi-year bull market, so now might be a good entry point. On morality and ethics: Numinus may not have a 1B valuation like MMED (with 0 revenue), but by supporting a company that is focused on natural healing and accessibility it is a step in a direction away from the big pharma method of `extracting value from` towards the team human (podcast) method of `creating value for`. And I believe that is what the mushrooms want :). How does investing help Numinus Wellness: A higher stock price allows for things such as uplisting to the TSX and NYSE which gives them more access to capital. Also, investor support allows them to obtain capital at a higher valuation. Full disclosure: I bought NUMI at 28c, have sold off portions several time for a variety of reasons, and now am dollar cost averaging in again during sideways movement and am focusing on managing risk. This is my first chart publish. I will appreciate all feedback, critical or otherwise. This is not financial advice.
NLong
by jtorkr
12
$PFE - Key Levels and Analysis$PFE - Key Levels and Analysis So it looks like It might be time to start a position in PFE… Target 45.92, or double position at 38.30 @Smartdaytrading I’m not sure if you saw this since the last post, its right at that projected buy level. This is definitely on my radar for tomorrow. —————— I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your due diligence. If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can. Have fun, y’all!!
NYSE:PFELong
by SPYder_QQQueen_Trading
2
BABA - HUGE OPTIONS PLAY - FALLING WEDGE + CHANNELAll, BABA is PRIMED here. Just a question of has it hit bottom. I would wait for break or daily candles conformation personally, but then i'd be all in here. This should break the falling wedge and hit the top of the downtrend channel. Huge plays here. This should take more of your attention than any small cap etc stocks. Make sure to set many alerts on this. Telling you this is worth big returns could see 180-200 by end of 2021. Especially holidays nearing etc.
NYSE:BABALong
by DigitalData
2
SPRB - 8M FLOAT - WORTH X2-X3 CURRENT PRICEAll, I am already scaled in big here. I am without a doubt this stock will at least double. ***KEEP IN MIND THIS IS AN 8M FLOAT COMPANY 1. Do your own DD you will notice all that has really happened is low float short sellers have just railed the price down 2. This companies price targets are insane not to mention 8M float will make this EXPLODE on any good news. The company is already undervalued + postiive news of any kind just blows this baby to the moon. Except here the moon is probably where it SHOULD be. 3. Financially speaking easily in great position no chance of offerings 4. Promising company overall 5. This downtrend looks awful, but is purely short sellers and look at the length of the time on market. This looks like it may happen soon, but either way I will happily add large position scales into this stock and simply wait. I really think at some point even a year from now we see 20+. The question is do you want to chase stocks daily, weekly or scale in. Either way set alers and volume alerts.
NASDAQ:SPRBLong
by DigitalData
The biotech era possibilities: reverse aging, cure cancer, ...A little intro to the biotech cycle... It could be real big. RNA technology can do a little bit more than tell your genes to produce spike protein. It could be used to fight cancer. It could also be used to increase life expectancy from 75 years to perhaps 90. And more importantly, make people age slower as well as kill "deficient" cells involved in aging. This means "prime" and "old age" would go from 25-50 and 50-75 to 25-60 and 60-90. Can you imagine? Of course this is not eternal life, but us humans prime for what seems like such a short time, especially as our life expectancy increase. You get to 25 and it's a race. By 50 it's over. At 35 you're already basically halfway through and missed on so much prossibly. But if you got until 60 then it would make a significant difference. You life would not be "over" just a few years after reaching adulthood. A while ago they came up with solutions but they had a little downside: it was highly cancerigenous. Research has improved, and if people don't revert to the stone age soon (no guarentee about that), it will continue. Plenty of treatments (injections, drugs, not RNA modifications) have been tested, and we have seen "70 year old" mice run faster than "25 year olds". They have been tested on various mammals and plants. And to my knowledge, 1 human. David Sinclair, a genetician that looks at least 10 years younger than he is. Not going to lie, the first people to get access to this, after the innovators (the few professors testing it on themselves) will be rich people. Anti-ageing through DNA therapy got to be cheaper and work better than weekly injections of 5 products + 25 other products to counter the side effects. RNA also is used to fight rare diseases, genetic disorders, but this concerns a tiny part of the population. It's nice and all, but let's be honest, most people care way more about increasing everyone's (and their) healthy life spans. Other uses: Vaccines. Obviously. Hunger management (you could also just ban obesity like Japan or ban the industry from dumping trucks of sugar and salt in their food to make people hungry). Faster fracture repair (maybe send gene instructions temporarly) Cure all sorts of handicaps (up to 10% of the population) Less very dumb people (that are unemployable)? Hair loss Color blindness Finally fix these teeth constantly getting damaged by bacteria Regrow an arm? Some cool sci-fi stuff? X-ray vision maybe? Idk unlimited possibilities A huge market bubble since "unlimited possibilities" Oh I can already see it Right now they are showing the population that RNA tech isn't scary by using them all (most of the pop) as guinea pigs and force vaccinating a lot of people. But I think they are calming down. These guys aren't that bright but at some point they might figure out if they insist too much they will alienate people and make them ultra-conservative and anti-vaxx and anti-everything. The boomers in power don't have long, so of course they are in a hurry to push this tech at any cost. Funny. They are desperate. The only western president that is young is Macron and OF COURSE his wife is like 80 or something. The risk is MOAR mass hysteria, MORE euphorism, so I think ultimately people will get greedy and go after more and more half tested rushed treatments, and traders should know the outcome: eventually, a catastrophe. Mass deaths followed by reverting back to ultra conservative values. Good buy on the next major bear market (this company or whichever one survives). But investing in this is not even the most interesting part.
NASDAQ:MRNA
by MrRenev
1
$EDSAEdesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care. An independent Data and Safety Monitoring Board concluded that "a clinically important efficacy signal" was detected and that the study "met its objective." The DSMB recommended continuation of the study into a Phase 3 trial. "The strong effect in reducing death in the most critically ill hospitalized patients who have been treated with systemic corticosteroids, including dexamethasone, and IL-6 inhibitors, shows the potential life-saving impact of this drug, irrespective of SARS-CoV-2 variant," said Par Nijhawan, CEO of Edesa Biotech. Edesa Biotech is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases. Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
NASDAQ:EDSALong
by BADQOMOCAWGOWLD
$IPHAKey Words: Innate Pharma S.A. (NASDAQ: IPHA) shares gained 40.9% to close at $8.10 as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology (ESMO21) Congress 2021. SVB Leerink maintained Innate Pharma with an Outperform and raised the price target from $7 to $9. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
NASDAQ:IPHALong
by BADQOMOCAWGOWLD
$CRVSCorvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer. Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
NASDAQ:CRVSLong
by BADQOMOCAWGOWLD
$LPTX Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress - DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer - Additional data presented today showed responses to treatment are independent of PD-L1 expression, with 79% ORR in patients with PD-L1 low (CPS < 5) tumors - Company to host conference call on Friday, September 17, 2021 at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 16, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress. The Company will host a conference call on Friday, September 17, 2021 to discuss preliminary results from the study. The Company announced positive initial data from the DisTinGuish study on Monday, September 13, 2021 based on 25 G/GEJ patients enrolled in the trial that showed DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy was well tolerated with compelling activity. The results presented at the ESMO Congress today included additional patient data stratified by tumoral PD-L1 expression levels based on visually-estimated combined positive score (vCPS), showing that robust objective clinical responses can be achieved from this combination regimen independently of PD-L1 expression. "Initial data from this trial have shown that patients with high levels of DKK1 expression, a group with a poor prognosis, had encouraging responses to treatment. The additional data presented today show evidence that not only is DKK1 a critical biomarker in predicting response to DKN-01 and tislelizumab therapy, but also that the combination can induce deep responses regardless of the patient's PD-L1 status, including particularly poor prognosis patients with both low PD-L1 and high DKK1," said Samuel Klempner, MD, Member of the Faculty at Massachusetts General Hospital Cancer Center and Harvard Medical School. "Taken together, these are promising results for the combination therapy of DKN-01 with tislelizumab and chemotherapy in first line patients with gastric or gastroesophageal junction cancers." About the DisTinGuish Study The DisTinGuish study (NCT04363801) is a Phase 2a study of DKN-01 in combination with tislelizumab, an anti-PD-1 antibody, with or without chemotherapy as first-line or second-line therapy in patients with inoperable, locally advanced, G/GEJ adenocarcinoma. The study is being conducted in two parts in the United States and the Republic of Korea. Enrollment of Part A has been completed with 25 first-line HER2- G/GEJ cancer patients whose tumors express either high levels of DKK1 (DKK1-high) or low levels of DKK1 (DKK1-low). Part B of the study will enroll up to 48 patients with second-line, DKK1-high G/GEJ cancer. Leap is conducting this combination study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Key Findings Among patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in DKK1-high patients and 56% in DKK1-low patients Response was independent of PD-L1 expression, and particularly strong in the less favorable to checkpoint inhibitor therapy, PD-L1 low (vCPS < 5), population DKK1 expression and PD-L1 expression are not correlated Median duration of response and progression-free survival data are not yet mature, and patient follow-up continues Twenty-five first-line patients were enrolled, and as of the cut-off date of the presentation, 15 patients had experienced a partial response (PR), six patients had a best response of stable disease (SD), one patient was non-evaluable for response (NE), and three patients were unable to complete a full cycle of DKN-01 therapy (non-modified ITT (mITT)). Among the 21 patients that had RNAscope® DKK1 expression available, 12 were DKK1-high and 9 were DKK1-low . Among the 20 patients that had PD-L1 expression available, 14 were PD-L1 low vCPS < 5 and 6 were PD-L1 high vCPS > 5 . A copy of the poster presentation is available on the Company's website at www.leaptx.com Conference Call Leap will host a conference call on Friday, September 17, 2021 at 8:00 a.m. Eastern Time to further discuss the data. In addition to Leap's executive management team, Dr. Jaffer Ajani of M.D. Anderson Cancer Center and Dr. Samuel Klempner of Massachusetts General Hospital will be on the call. The call can be accessed by dialing (866) 589-0108 (U.S. and Canada) or (409) 231-2048 (international). The passcode for the conference call is 1729397. The presentation will be webcast live and may be accessed on the Investors page of the Company's website at investors.leaptx.com where a replay of the event will also be available for a limited time. About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
NASDAQ:LPTXLong
by BADQOMOCAWGOWLD
1